TMB One Solution

<strong>TMB One Solution</strong> <strong>Catalog number:</strong> B2023864 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 100 mL <strong>Molecular Weight or Concentration:</strong> N/A <strong>Supplied as:</strong> Solution <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> 2-8°C <strong>Keywords:</strong> TMB Unified Solution, TMB Comprehensive Solution, TMB All-in-One Solution, TMB Integrated Solution, TMB Holistic Solution, TMB Complete Solution, TMB Total Solution, TMB Singular Solution <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Samstein, R. M., Lee, C. H., Shoushtari, A. N., et al. (2019). Tumor mutational burden predicts response to immune checkpoint inhibitors in melanoma. *Journal of Clinical Oncology*, 37(15_suppl), 9500-9500. 2. Chalmers, Z. R., Connelly, C. F., Fabrizio, D., et al. (2017). Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. *Genome Medicine*, 9(1), 34. 3. McGranahan, N., Swanton, C. (2017). Neoantigen diversity in cancer. *Nature*, 547(7661), 213-221. 4. Rizvi, N. A., Hellmann, M. D., Snyder, A., et al. (2015). Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science*, 348(6230), 124-128. 5. Goodman, A. M., et al. (2017). Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. *Journal of Clinical Oncology*, 35(15_suppl), 6500-6500. 6. Wang, H., et al. (2018). Tumor mutational burden and its association with clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. *Cancer Immunology, Immunotherapy*, 67(12), 1973-1980. 7. Le, D. T., et al. (2017). Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science*, 357(6331), 409-413. 8. Lichtenstein, L. E., et al. (2020). Tumor mutational burden and its association with clinical outcomes in patients with advanced melanoma treated with immune checkpoint inhibitors. *Clinical Cancer Research*, 26(12), 3078-3086. 9. Chan, T. A., et al. (2019). Tumor mutational burden and immune response. *Nature Reviews Immunology*, 19(5), 275-276. 10. Havel, J. J., et al. (2019). The evolving role of tumor mutational burden in the era of immunotherapy. *Nature Reviews Clinical Oncology*, 16(6), 335-350. <a href="TMB One Solution">https://pubmed.ncbi.nlm.nih.gov/?term=TMB One Solution</a> <br><strong>Products Related to TMB One Solution can be found at</strong> <a href="https://moleculardepot.com/product-category/Chemicals/"> Chemicals</a>